Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Kosuke Takemura(Japanese Foundation For Cancer Research), Daniel Yick Chin Heng(University of Calgary), David Maj(University of Calgary), Eddy Saad(Dana-Farber Cancer Institute), Camillo Porta(University of Pavia), Naveen S. Basappa, Razane El Hajj Chehade(Dana-Farber Cancer Institute), J. Connor Wells(Queen's University), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Sumanta K. Pal(City of Hope), Martín Zarbá(University of Calgary), Toni K. Choueiri(Harvard University), Rana R. McKay(University of California San Diego), Frede Donskov(Aarhus University Hospital), Jae‐Lyun Lee(Ulsan College), Neeraj Agarwal(University of Utah), Marc Eid(Harvard University), Evon Jude(Olivia Newton-John Cancer Wellness & Research Centre), Renée Maria Saliby(Yale University), Jeffrey Graham(University of Calgary)
Cited by 2
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k